Co-Diagnostics, Inc. CODX

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will represent the Company at two global health events during the 81st Session of the United Nations General Assembly in New York City:

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Seth Egan, Chief Commercialization Officer, will participate in the Global Health Technologies Coalition (GHTC) and Adjuvant Capital roundtable discussion on September 22, 2026, in New York, NY.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will participate in the upcoming joint WHO/Unitaid/UNAIDS Annual Consultation Meeting. Joseph Featherstone, Executive Vice President of Business Development, will represent Co-Dx at the annual meeting, which will be held at the World Health Organization (WHO) headquarters in Geneva, Switzerland,

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests and ReadyGo Diagnostics Ltd. ("ReadyGo"), a UK-based developer of field sample-preparation technology, today announced that the companies are collaborating to evaluate the potential use of ReadyGo's sample-preparation technology with the Co-Dx PCR platform for blood-based molecular testing at the point of need, with an

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will host a press conference and live webcast Wednesday, Sept. 16, 2026, at 10:30 a.m. Eastern Time.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the launch of its integrated cloud infrastructure in India. The deployment is intended to support the Company's ongoing clinical studies for its point-of-care Mycobacterium tuberculosis (MTB) test while establishing the digital foundation for future deployment of the Co-Dx® PCR platform* throughout the

Co-Diagnostics, Inc.(Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the first international deployment of its Vector Smart® mosquito surveillance platform, to include shipments of laboratory equipment, consumables, and other mosquito abatement reagents and materials to an overseas United States Air Force ("USAF") base.

Co-Diagnostics, Inc.(Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Company Chief Commercialization Officer Seth Egan recently participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable event, held on Thursday, August 13 and moderated by the intellectual property law firm Maschoff Brennen in Salt Lake City, Utah.

Moby summary of Co-Diagnostics, Inc.'s Q2 2026 earnings call

Co-Diagnostics Inc (CODX) narrows Q2 2026 net loss to $6.3 million while advancing key regulatory submissions for its flu/RSV panel and tuberculosis test.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the second quarter ended June 30, 2026.

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has submitted a Dual 510(k) premarket notification, with a concurrent CLIA Waiver by Application, to the U.S. Food and Drug Administration ("FDA") for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro® instrument*. The submission follows the Company's previously

OraSure Technologies (NASDAQ:OSUR) reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth in sample-management products supported results. President and Chief Executive Officer Carrie Eglin

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, has sent test kits of the SARAGENE® Bundibugyo Virus Test to a third-party laboratory for evaluation following a request by the India Centre for Cellular and Molecular Platforms ("C-CAMP"), an initiative supported by the

Co-Diagnostics Inc. (NASDAQ:CODX), a molecular diagnostics firm, announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., shipped evaluation kits of its SARAGENE Bundibugyo Virus Test to an independent testing facility. The distribution was initiated at the behest of the India Center for Cellular and Molecular Platforms (C-CAMP), an initiative backed by the India Department of Biotechnology. Expanding Point-Of-Care Diagnostics For Virus Testing Alongside deploying these test kits,

Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Company's joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro® instrument.

Co-Diagnostics Inc. (NASDAQ:CODX) on Wednesday said CoSara Diagnostics Pvt. Ltd, its joint venture in India, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro instrument. The molecular diagnostics company said the initiation of these clinical studies marks another critical milestone for the Co-Dx PCR platform, following the company’s previously announced shipment of PCR Pro instruments, mycobacterium tuberculosis (TB or MTB) test kits and proprietary sample preparati